Biovitrum selects Megapharm as distributor in Israel



Stockholm - July 8, 2009. Biovitrum AB (publ) (STO: BVT) has entered
an exclusive distribution and marketing agreement with Megapharm Ltd.
allowing Biovitrum's products Kineret® and Kepivance® to be
commercialized in Israel.

Megapharm has in the contract agreed to maintain a sales organization
to promote Kineret® and Kepivance® during 5 years. The products will
be filed for a market authorization to the Israeli authorities this
autumn and an approval is expected during 2010.

 "We are excited about the opportunity to work with Megapharm, a
leading biotech marketing company in Israel. We are certain that
Megapharm will be able to effectively provide our innovative products
to patients who need them and thereby maximize the potential of the
products," said Martin Nicklasson, CEO at Biovitrum.

Miron Drucker, CEO and founder of Megapharm, said, "We are very
excited to conclude this agreement with Biovitrum and to lend our
expertise to successfully market and maximize the potential of
Kineret and Kepivance in Israel. This will help to further reinforce
our biologics portfolio and maintain our prominent position in the
relevant therapeutic areas. We are proud to be associated with
Biovitrum, and look forward to a long term and fruitful
relationship".

About Kineret® (anakinra)
Information about Kineret® can be found at:
http://www.kineretrx.com/

Healthcare professionals should refer to and rely upon the PDR
(Physician's Desk Reference) or the corresponding national labeling
texts, and not the information above.

About Kepivance® (palifermin)
Information about Kepivance® can be found at :
 http://www.kepivance.com/

Healthcare professionals should refer to and rely upon the PDR
(Physician's Desk Reference) or the corresponding national labeling
texts, and not the information above



About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. The company has revenues of approximately SEK 1.2
billion and around 400 employees. The company head office is located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For
more information please visit www.biovitrum.com

About Megapharm
Megapharm Ltd. is one of the leading private biotech, pharmaceutical
and medical nutrition marketing companies in Israel with a strong
biotech orientation, exclusively representing a number of major
American and European pharmaceutical companies. Megapharm has
demonstrated dynamic sales growth by developing a strong company
presence and expertise in select therapeutic areas, and diversified
segments of the healthcare business. The company also has a
recognized and proven track record for obtaining reimbursement and
inclusion of its products in all the health funds in Israel. For more
information see www.megapharm.co.il

For more information please contact:
Biovitrum
Martin Nicklasson, CEO
Phone: +46 8 697 2545

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

Megapharm
Miron Drucker, CEO
Phone: +972 9 7604596
admin@megapharm.co.il

Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on July 8, 2009 at 8.30
a.m. CET.

Attachments

Press Release in PDF format.pdf